SBIR/STTR Research Award

Validating the MicroKine Assay for Use in Identifying Personalized Precision Therapies for Pediatric Sepsis

Award identifier f0a747e294bde27366cfdcb29b3b8e994f9d0af24eff75b166d03b7b1e1eda7eAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$224,944

Program and phase

STTR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
PreDxion Bio, Inc.
Proposal award date
2018-01-01
Contract end date
2018-09-30
UEI
E5VUVDJPZ6J1
Solicitation number
PAR13-091
Topic code
NICHD

Research abstract

Project Summary Abstract PreDxion BioLLC is a precision medicine diagnostic company developing an assay platformthe MicroKineassay cartridge and readerthat measures serum proteins in less thanminutes from a single drop of bloodThis fastactionable information allows for the first time individualized precision medicine aimed at reducing pediatric morbidity and mortality in pediatric sepsisthe number one killer of children worldwideThe goal of this STTR is to move the current research grade MicroKineplatform to a validatedscalablecommercial grade alpha platformPhase Ithen to a fully automated beta platformPhase IIwhile demonstrating the feasibility of using the platform in the clinical workflowUsing serum sample from pediatric patients with sepsis PreDxion will validate the MicroKineplatform demonstrating the feasibility of rapid risk stratification and identification of therapeutic targets by addressing the following aimsSpecific Aim Idetermine the feasibility of the alpha version of the MicroKineassay to rapidly risk stratify pediatric patients with severe sepsis and Specific Aim IIdemonstrate feasibility of rapidly determining the serum cytokines values in high risk septic pediatric patientsSuccessful commercialization of the MicroKineplatform will provide the basis for expanding the current sepsis guidelines to individualized precision guidelines in high risk individuals reducing the high rates of mortality in these individuals Project Narrative PreDxion Bio is developing a rapid serum protein assayMicroKinethat will provide clinicians information to guide precise individual therapies to children at highest risk from dying from sepsisthe number one killer of children worldwideThe assay would change the current way children with sepsis are treated by providing serum inflammatory protein levels in less thanminutes allowing clinicians to act quicklyThe MicroKineassay provides this information from a drop of blooda necessity when caring for children

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.